NCT04540900View on ClinicalTrials.gov

A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

October 7, 2020

Primary Completion Date

October 16, 2024

Study Completion Date

May 31, 2029

Conditions
Skin RoughnessWrinkleFine LinesSkin Thickness
Interventions
BIOLOGICAL

KB301

non-integrating HSV-1 vector expressing human type III collagen

OTHER

Placebo

sterile isotonic saline

Trial Locations (4)

33180

Skin and Cancer Associates, LLP. D/B/A Center for Clinical and Cosmetic Research, Aventura

92663

Steve Yoelin, MD Medical Associates, Inc., Newport Beach

92688

Mission Dermatology, Rancho Santa Margarita

95008

Aesthetx, Campbell

Sponsors
All Listed Sponsors
lead

Krystal Biotech, Inc.

INDUSTRY

NCT04540900 - A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions | Biotech Hunter | Biotech Hunter